Research Fellow, University of South Australia


My research is in multidisciplinary field merging materials science and its application in biomedical field. I am developing multifunctional nanocarriers as drug delivery vehicle that can be used to kill cancer cells. In conventional cancer chemotherapy the dosage of drug is high that causes huge impact to normal healthy cells. Also the bioavailability of anticancer drugs is very less. To overcome the disadvantages associated with conventional chemotherapy, we develop new drug formulation based on nanoparticles. Due to the small size and large surface area, the dosage of drug can be considerably reduced and our nanoformulation enhances the bioavailability and efficacy of drugs. To add specificity of our nanocarrier we decorate our nanocarrier with special cancer targeting groups that goes and binds cancer cells and deliver anticancer drug to them, thus killing cancer cells and not the healthy neighbouring cells.
In addition, we also aim to incorporate diagnostic agents to our nanocarrier that can offer imaging potential. In summary, I aim to develop multifunctional (therapeutic and diagnostic) nanocarrier that have the potential to kill cancer cells (any type of cancer) and simultaneously image the effect of drug on tumour. Currently I am working on mesoporous silica nanocarriers as drug delivery vehicles against prostate cancer. We will be expanding our studies to various cancer types and with different anticancer drugs and exploit different cancer targeting groups.


The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery.

Abstract: Nano-scale formulations are being developed to improve the delivery of orally administered medicines, and the interactions between nanoformulations and the gastrointestinal luminal, mucosal and epithelial environment is currently being investigated. The mucosal surface of the gastrointestinal tract is capable of trapping and eliminating large particles and pathogens as part of the natural defences of the body, it is becoming clearer that nanoformulation properties such as particle size, charge, and shape, as well as mucous properties such as viscoelasticity, thickness, density, and turn-over time are all relevant to these interactions. However, progress has been slow to utilise this information to produce effective mucous-penetrating particles. Areas covered: This review focuses on delivery method of nanomedicines both into and across the gastrointestinal mucosal surface, and aims to summarise the biological barriers that exist to successful oral nanomedicine delivery and how these barriers may be investigated and overcome. Expert commentary: Despite successes in the laboratory, no nanotechnology-enabled products are currently in clinical use which either specifically target the intestinal mucous surface or cross the epithelial barrier intact. New nanomedicine-based treatments of local diseases (intestinal cancer, inflammation, infection) and systemic diseases are advancing towards clinical use, and offer genuine opportunities to improve therapy.

Pub.: 02 Nov '17, Pinned: 06 Nov '17

An overview on applications of gold nanoparticle for early diagnosis and targeted drug delivery to prostate cancer.

Abstract: Carcinoma of the prostate gland (PCa) is one of the most commonly diagnosed cancer diseases among men around the world. PCa has become the major considerable health and epidemic problem which causes death in men with a high prevalence and relatively lower mortality risk. The inability of conventional diagnosis tools to detect cancer at an early and potentially curable stage further hinders effective treatment options and spur demand for improved technologies. Nanoparticles are emerging as a versatile tool for disease diagnosis to therapy. Gold nanoparticles (AuNPs) have a huge potential in targeted drug delivery and detection of cancerous cells. Diverse predominant distinctive properties of gold nanomaterials and their effective functionalization make them a suitable material for early diagnosis and effective treatment of cancer.To summarize the recent research on the development of multifunctional AuNPs based nanoformulations for early diagnosis and targeted drug delivery to prostate cancer. Further, discussion on the salient features of gold nanostructures and its evaluation of extremely attractive vectors in prostate cancer diagnosis and treatments.This review summarizes the use of AuNPs based nanoformulations in cancer diagnostics and therapy, which has been recognized as an important platform as smart materials for clinical application. The ability to tune the size, shape and the physical properties of AuNPs along with their low toxicity, biocompatibility and large surface chemistry makes them as a promising candidate for clinical use.

Pub.: 02 Nov '17, Pinned: 06 Nov '17